Medincell
French biotech based near Montpellier, specialised in long-acting injectable formulations through its BEPO® platform. FY 2025-26 marks the acceleration of the transition toward a stable royalty model: UZEDY® (Teva, schizophrenia) generated $215M in net sales (+52.5% YoY), and olanzapine LAI (TEV-‘749) is expected to launch in the United States in Q4 2026.
Investment thesis
- 01
Patented BEPO® platform, validated through regulatory approvals (UZEDY®, in progress for olanzapine LAI) — a durable and repeatable competitive moat.
- 02
Asset-light model: commercialisation outsourced to industrial partners (Teva, AbbVie); Medincell captures the upside through royalties and milestone payments without sales force commitment.
- 03
UZEDY® (risperidone LAI, schizophrenia) accelerating commercially: $215M of Teva net sales in FY 2025-26 vs $141M in the prior year (+52.5%); associated Medincell royalties of €9.3M now structurally anchor the P&L.
- 04
Olanzapine LAI (TEV-‘749, built on Medincell's proprietary SteadyTeq™ technology) approaching market launch: FDA NDA accepted on 20 February 2026, EMA MAA accepted on 21 May 2026, US launch targeted Q4 2026 by Teva — milestones of $4M (US) and $3M (EU) on approval, mid-to-high single-digit royalties on net sales.
- 05
AbbVie partnership: the first co-developed programme is progressing toward the initiation of clinical development, broadening the portfolio beyond psychiatry.
- 06
Long-acting ivermectin programme: a non-exclusive license has been granted to the Medicines Patent Pool for low- and middle-income countries — a differentiated public-health angle.
- 07
Balance sheet reinforced in March 2026 by a €48.2M raise from US and European healthcare investors; total liquidity €84.8M (including €62.8M cash) at year-end. In July 2026, a non-dilutive refinancing — €28M of new European bank loans, with no covenant or equity-linked instruments — extended debt maturity by more than 3 years to mid-2031 and funded the early repayment of a €20M tranche of the EIB loan: a financial structure aligned with the ramp-up of combined UZEDY® + olanzapine LAI royalties.
Catalysts
US launch of olanzapine LAI (TEV-‘749) by Teva
FDA approval then market launch expected in Q4 2026 per Teva's stated timeline; $4M US approval milestone, start of mid-to-high single-digit royalty flow.
EMA review of olanzapine LAI (MAA accepted 21 May 2026)
With the MAA accepted, the second key market is open; the next expected milestone is the European decision, triggering the $3M milestone and additional royalties on EU sales.
UZEDY® royalty trajectory
Confirmed ramp-up: record UZEDY® net sales of $77M in Q2 2026 (+43% YoY, prescriptions +63% YoY), with Teva raising its 2026 guidance to $270–290M (from $250–280M). Medincell earns mid-to-high single-digit royalties and remains eligible for up to $105M in commercial milestone payments.
First AbbVie programme entering clinical development
Expected start of the first clinical trial co-developed with AbbVie — first visible milestone of the partnership beyond the deal signing.
New partnerships / platform extensions
Medincell's ability to sign new reformulation deals: a key signal of the industry's perceived value for BEPO® after the dual UZEDY® + olanzapine LAI validation.
Combined general meeting
Convening notice published in the BALO on 26 August 2026: a combined ordinary and extraordinary general meeting on Wednesday 30 September 2026 at 6:00pm at the Jacou head office, covering 31 resolutions. The 6th resolution acknowledges the expiry of Virginie Lleu's term and proposes appointing Dr Elisabeth Svanberg for four years, until the AGM approving the FY 2029-30 accounts. The extraordinary part notably covers a capital reduction by cancellation of treasury shares (15th) and a full set of capital-increase delegations with or without pre-emptive rights (16th to 22nd). A moment of dialogue with management on royalty-transition execution, capital allocation after the €48.2M raise, and partnership strategy.
Risks
Short-term revenue concentration
At this stage, recurring revenue rests almost entirely on UZEDY® through Teva. The arrival of olanzapine LAI royalties will reduce this concentration from late 2026, but diversification remains to be confirmed.
Dependence on partner commercial choices
Medincell does not directly control pricing, reimbursement or sales force decisions. The royalty trajectory depends on Teva execution (UZEDY®, soon olanzapine LAI), then AbbVie on the first clinical programme.
FDA / EMA regulatory risk on olanzapine LAI
US NDA acceptance (February 2026) and EMA MAA acceptance (May 2026) do not guarantee final approvals; a delay or a complete-response letter from either authority would push back the US royalty start (targeted Q4 2026) or the subsequent EU decision.
Income statement still loss-making
Operating loss of €(20.8)M on the closing year for €24.3M of revenue and €45M of Opex (+17% YoY). The path to profitability depends on the dual UZEDY® + olanzapine LAI engine; the March 2026 raise (€48.2M) secures the horizon but further dilution remains possible if the trajectory slips.
Valuation multiple volatility
The market oscillates between a pharma-services / royalties reading and a biotech / pipeline reading, with significant multiple gaps. The ongoing narrative transition may amplify share-price moves.
Calendar
- 21 mai 2026Olanzapine LAI MAA accepted by EMA — review ongoingClinical
- Q4 2026Targeted FDA approval + US launch of olanzapine LAICorporate
- 14–25 sept. 2026Investor conference tour · Morgan Stanley 24th Annual Global Healthcare and H.C. Wainwright 28th Annual Global Investment (14–16 Sept.), Jefferies Healthcare C-Suite Back-to-School Fireside Chat (22 Sept.), BioCentury Annual Grand Rounds Europe in Amsterdam (23–25 Sept.)Conference
- 30 sept. 2026Combined general meeting (31 resolutions) · Jacou, 6:00 p.m. CEST; remote voting open until 29 Sept.AGM
- 8 déc. 2026H1 FY 2026-27 resultsEarnings
- 2026-2027Partner pipeline milestones (AbbVie, Teva)Clinical
Governance
Stable historical leadership around the co-founders, now complemented by a dedicated medical function: Edna Venneker, MD, was appointed Chief Medical Officer on 1 September 2026, having previously been Head of Development and Senior Vice President at Grünenthal, where she also served as Deputy Chief Medical Officer. Board renewal underway since 2025: the appointment of Dr Elisabeth Svanberg as an independent director, proposed at the 30 September 2026 AGM (6th resolution, four-year term, replacing Virginie Lleu whose term expires; expected to chair the Remuneration & Nomination Committee), would bring the share of the board renewed since 2025 to 50%. Capital open to an international institutional shareholder base reinforced in March 2026 by a €48.2M capital increase from US and European healthcare investors. Solid retail shareholder community, especially active at AGMs. CapCordia documents resolutions, votes and management communications, with particular attention to the execution of the transition to the royalty model.
This file is editorial and does not constitute investment advice. Individual shareholders are responsible for their own decisions.